Open AccessEFFICACY AND SAFETY OF IRON (III)–HYDROXIDE SUCROSE COMPLEX IN CORRECTION OF ANEMIA STAGE 5D CHRONIC KIDNEYDISEASE HEMODIALYSIS PATIENTS NOT TREATED BY ERYTHROPOIESIS–STIMULATING AGENTS (PROSPECTIVEANALYSIS)
Author(s) -
І. Dudar,
Iyrii Gonchar,
І. Shifris,
E. Krasjuk,
V. Savchuk,
Олена Лобода,
F. О. Pruskiy,
Viktor Krot,
Т. М. Nechiporuk,
Н. Т. Алексеева
Publication year - 2014
Publication title -
ukraïnsʹkij žurnal nefrologìï ta dìalìzu
Language(s) - English
Resource type - Journals
eISSN - 2616-7352
pISSN - 2304-0238
DOI - 10.31450/ukrjnd.4(44).2014.07
Subject(s) - medicine , transferrin saturation , hemodialysis , anemia , kidney disease , gastroenterology , transferrin , dialysis , adverse effect , iron sucrose , erythropoiesis , surgery , urology , iron deficiency , intravenous iron
The aim of study was to evaluat the efficacy and safety ofSUFER® (iron (III) sucrose complex) in correction of anemia stage 5D chronic kidney disease hemodialysis patients.
Methods. This study included thirty patients undergoing regular hemodialysis (mean age 48,81±3,24 years, mean duration of dialysis 30,43±9,25 months) with renal anemia and iron deficiency. All patients were treated with SUFER® intravenously 200 mg three times a week. Correction dose was determined according to the manufacturer’s recommendations.
Results. Mean level offerritin was significantly increased from 125,15 ± 21,46 ng / ml to 375,56 ± 64,12 ng / ml (p <0,001), transferrin saturation – from 17,48 ± 2,71% to 38,21 ± 4,90 ng / ml (p <0,001). 23 (76.67%) patients achieved target levels offerritin and transferrin, 12 (40% ) adverse events.
Conclusions. SUFER® is effective and safety drug in dialysis patients.